The imaging process provides the most time-efficient sequence with the highest lesion detection rate and conspicuity.
Gadolinium-enhanced T1-weighted volumetric interpolated breath-hold exam (VIBE) is best for detecting prostate cancer metastases, according to a study published in the American Journal of Roentgenology.
Researchers from Canada performed a prospective study to compare the diagnostic value of various MRI sequences used for whole-body (WB) 18F-fluorocholine (FCH) PET/MRI staging of patients with high-risk prostate cancer. The study included 58 patients with untreated high-risk prostate cancer. Ten patients underwent integrated WB FCH PET/MRI; 48 underwent FCH PET/CT and WB MRI. The researchers recorded metastatic sites and used histopathologic findings or clinical and imaging follow-up (or both) for standard of reference.
The results showed the gadolinium-enhanced T1-weighted volumetric interpolated breath-hold exam (VIBE) was the best of the four sequences:
Conspicuity of metastases on gadolinium-enhanced T1-weighted VIBE and WB DWI sequences was higher than that on Dixon T1-weighted sequences.
The researchers concluded that metastases from prostate cancer are best detected at DWI or gadolinium-enhanced T1-weighted VIBE sequences. The most time-efficient sequence with the highest lesion detection rate and conspicuity is gadolinium-enhanced T1-weighted VIBE.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.